stoxline Quote Chart Rank Option Currency Glossary
  
VistaGen Therapeutics, Inc. (VTGN)
3.69  -0.08 (-2.12%)    06-12 16:00
Open: 3.8
High: 3.89
Volume: 100,834
  
Pre. Close: 3.77
Low: 3.66
Market Cap: 100(M)
Technical analysis
2024-06-12 4:25:55 PM
Short term     
Mid term     
Targets 6-month :  5.01 1-year :  5.54
Resists First :  4.29 Second :  4.75
Pivot price 3.91
Supports First :  3.54 Second :  2.95
MAs MA(5) :  3.75 MA(20) :  4.05
MA(100) :  4.61 MA(250) :  4.26
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  17.8 D(3) :  13.2
RSI RSI(14): 28.6
52-week High :  24.7 Low :  1.62
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VTGN ] has closed above bottom band by 12.9%. Bollinger Bands are 40.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.9 - 3.92 3.92 - 3.94
Low: 3.6 - 3.63 3.63 - 3.65
Close: 3.65 - 3.69 3.69 - 3.73
Company Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Headline News

Thu, 13 Jun 2024
VistaGen Therapeutics Inc. at Risk: Market Turmoil and Economic Instability Threaten Financial Stability - TipRanks.com - TipRanks

Wed, 12 Jun 2024
ADAR1 Capital Management LLC Takes Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Tue, 11 Jun 2024
Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript - Seeking Alpha

Tue, 11 Jun 2024
Vistagen Therapeutics Inc (VTGN) Q4 2024 Earnings Call Transcript Highlights: Significant R&D Cost Reduction and ... - GuruFocus.com

Sun, 09 Jun 2024
Vistagen Therapeutics (VTGN) Set to Announce Earnings on Tuesday - Defense World

Wed, 24 Apr 2024
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression (NASDAQ:VTGN) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 27 (M)
Held by Insiders 1.549e+007 (%)
Held by Institutions 0.2 (%)
Shares Short 1,290 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.377e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 916.3 %
Return on Equity (ttm) -26.4 %
Qtrly Rev. Growth 1.04e+006 %
Gross Profit (p.s.) 187.1
Sales Per Share -64.57
EBITDA (p.s.) 0
Qtrly Earnings Growth -3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -26 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 0.55
Stock Dividends
Dividend 0
Forward Dividend 1.06e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android